Alnylam Pharmaceuticals Inc. (ALNY)

Trade ALNY now with
10/10/2019 7:33:56 AM Alnylam Files Marketing Authorization Of ONPATTRO In Brazil For Hereditary ATTR Amyloidosis With Polyneuropathy
9/13/2019 7:33:00 AM Alnylam Presents New Results Demonstrating Significant Association Of V122I
9/2/2019 4:02:42 AM Alnylam Provides Perspective On Positive Complete Results From ORION-11 Phase 3 Study Of Inclisiran
8/13/2019 7:33:29 AM Ironwood Pharma, Alnylam Pharma Enter U.S. GI Disease Education And Promotional Agreement For Givosiran In AHP
8/6/2019 8:05:14 AM Alnylam Pharma Q2 Loss Per Share $2.02 Vs Loss $1.63 Last Year
7/11/2019 8:32:59 AM Alnylam Names Jeff Poulton EVP And CFO; Manmeet Soni To Resign
7/1/2019 7:05:16 AM Alnylam Submits MAA To EMA For Givosiran For Acute Hepatic Porphyria
6/21/2019 7:02:57 AM Alnylam Announces New Advances In Its RNAi Therapeutics Platform
6/18/2019 8:05:00 AM Alnylam Announces Approval In Japan Of ONPATTRO For Hereditary ATTR Amyloidosis With Polyneuropathy
6/17/2019 7:16:31 AM Alnylam Reports Full Patient Enrollment In ILLUMINATE-A Phase 3 Study
6/17/2019 7:06:50 AM Alnylam Completes Enrollment For ILLUMINATE-A Phase 3 Study Of Lumasiran In Patients With PH1
6/13/2019 8:06:48 AM Alnylam To Report New Clinical Results For ONPATTRO At Peripheral Nerve Society Annual Meeting And EAN
6/5/2019 7:20:55 AM Alnylam Completes Rolling Submission Of NDA To FDA For Givosiran
5/31/2019 7:06:59 AM Alnylam Doses First Patient In Phase 1 Study Of ALN-AGT For The Treatment Of Hypertension
5/29/2019 8:07:19 AM Alnylam Appoints Kelley Boucher As SVP, CHRO And Kevin Fitzgerald SVP, CSO
5/1/2019 8:17:34 AM Alnylam Pharma Q1 GAAP Loss/Shr $1.73; Non-GAAP Loss/Shr $1.42